Current and historical daily P/E ratio for Applied Therapeutics Inc (
) from 2019 to Dec 02 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Applied Therapeutics stock (APLT) PE ratio as of Dec 02 2022 is 0.
More Details
Applied Therapeutics Inc (APLT) PE Ratio (TTM) Chart
Applied Therapeutics Inc (APLT) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 898
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Applied Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2022-12-03 | At Loss | 2022-09-29 | At Loss |
| 2022-12-01 | At Loss | 2022-09-28 | At Loss |
| 2022-11-30 | At Loss | 2022-09-27 | At Loss |
| 2022-11-29 | At Loss | 2022-09-26 | At Loss |
| 2022-11-28 | At Loss | 2022-09-23 | At Loss |
| 2022-11-25 | At Loss | 2022-09-22 | At Loss |
| 2022-11-23 | At Loss | 2022-09-21 | At Loss |
| 2022-11-22 | At Loss | 2022-09-20 | At Loss |
| 2022-11-21 | At Loss | 2022-09-19 | At Loss |
| 2022-11-18 | At Loss | 2022-09-16 | At Loss |
| 2022-11-17 | At Loss | 2022-09-15 | At Loss |
| 2022-11-16 | At Loss | 2022-09-14 | At Loss |
| 2022-11-15 | At Loss | 2022-09-13 | At Loss |
| 2022-11-14 | At Loss | 2022-09-12 | At Loss |
| 2022-11-11 | At Loss | 2022-09-09 | At Loss |
| 2022-11-10 | At Loss | 2022-09-08 | At Loss |
| 2022-11-09 | At Loss | 2022-09-07 | At Loss |
| 2022-11-08 | At Loss | 2022-09-06 | At Loss |
| 2022-11-07 | At Loss | 2022-09-02 | At Loss |
| 2022-11-04 | At Loss | 2022-09-01 | At Loss |
| 2022-11-03 | At Loss | 2022-08-31 | At Loss |
| 2022-11-02 | At Loss | 2022-08-30 | At Loss |
| 2022-11-01 | At Loss | 2022-08-29 | At Loss |
| 2022-10-31 | At Loss | 2022-08-26 | At Loss |
| 2022-10-28 | At Loss | 2022-08-25 | At Loss |
| 2022-10-27 | At Loss | 2022-08-24 | At Loss |
| 2022-10-26 | At Loss | 2022-08-23 | At Loss |
| 2022-10-25 | At Loss | 2022-08-22 | At Loss |
| 2022-10-24 | At Loss | 2022-08-19 | At Loss |
| 2022-10-21 | At Loss | 2022-08-18 | At Loss |
| 2022-10-20 | At Loss | 2022-08-17 | At Loss |
| 2022-10-19 | At Loss | 2022-08-16 | At Loss |
| 2022-10-18 | At Loss | 2022-08-15 | At Loss |
| 2022-10-17 | At Loss | 2022-08-12 | At Loss |
| 2022-10-14 | At Loss | 2022-08-11 | At Loss |
| 2022-10-13 | At Loss | 2022-08-10 | At Loss |
| 2022-10-12 | At Loss | 2022-08-09 | At Loss |
| 2022-10-11 | At Loss | 2022-08-08 | At Loss |
| 2022-10-10 | At Loss | 2022-08-05 | At Loss |
| 2022-10-07 | At Loss | 2022-08-04 | At Loss |
| 2022-10-06 | At Loss | 2022-08-03 | At Loss |
| 2022-10-05 | At Loss | 2022-08-02 | At Loss |
| 2022-10-04 | At Loss | 2022-08-01 | At Loss |
| 2022-10-03 | At Loss | 2022-07-29 | At Loss |
| 2022-09-30 | At Loss | 2022-07-28 | At Loss |
Applied Therapeutics Inc (APLT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Applied Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
2UV.Germany
•
APLT.USA
Description
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.